Search
Enlivex Therapeutics Ltd
ENLVAdd to Watchlist
0.721USD
-0.012-1.58%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
173.70MMarket Cap
0.03P/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
-1.58%
5 Days
-6.42%
1 Month
-12.12%
6 Months
-27.31%
Year to Date
+2.47%
1 Year
-30.04%
TradingKey Stock Score of Enlivex Therapeutics Ltd
Currency: USD Updated: 2026-05-15Key Insights
Enlivex Therapeutics Ltd's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 185 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 20.00.In the medium term, the stock price is expected to trend down.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Enlivex Therapeutics Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Enlivex Therapeutics Ltd Highlights
StrengthsRisks
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 0.03, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 2.13M shares, decreasing 41.59% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 61.65K shares of this stock.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
20.000
Target Price
+2630.75%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Enlivex Therapeutics Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Enlivex Therapeutics Ltd Info
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Ticker SymbolENLV
CompanyEnlivex Therapeutics Ltd
CEOHershkovitz (Oren)
Websitehttps://www.enlivex.com/
Related Instruments
-0.18%
-1.77%
-0.18%
-1.13%
-1.83%
-1.79%
-2.95%
-1.88%
-2.31%
-1.63%
+0.41%
-2.99%
-0.37%
-2.53%
+1.79%
-2.05%
0.00%
-0.12%
-2.77%
+0.42%Popular Instruments
102.160
+3.297 (+3.33%)
300.230
+2.020 (+0.68%)
225.320
-10.420 (-4.42%)
4538.710
-111.520 (-2.40%)
482.020
-7.130 (-1.46%)
1407.610
+24.890 (+1.80%)
724.660
-51.350 (-6.62%)
396.780
-4.290 (-1.07%)
77925.460
-1167.660 (-1.48%)
422.240
-21.060 (-4.75%)
